Evolution of treatment practices and outcomes in multiple myeloma during 2013–2022: a Finnish real world registry study
While advancements of novel drugs have resulted in a notable survival benefit for patients undergoing SCT, the survival of non-SCT-patients has remained comparatively static. New approaches in the treatment of MM for elderly and frail non-SCT patients are warranted.
Authors
- Marika Waltari
- Johanna Vikkula (ORCID: https://orcid.org/0000-0002-5750-6120)
- Katja Maria Närhi (ORCID: https://orcid.org/0000-0002-9537-4392)
- Jonna Eeva
- Anu Partanen (ORCID: https://orcid.org/0000-0002-5634-2582)
- Mervi Putkonen
- Riikka Mattila (ORCID: https://orcid.org/0000-0002-7707-2411)
Institutions
- Johnson & Johnson (United States) (US)
- Kuopio University Hospital (FI)
- Tampere University Hospital (FI)
- Tampere University (FI)
- Johnson & Johnson (India) (IN)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-05-05
- DOI
- https://doi.org/10.2340/1651-226x.2025.42647
- Citations
- 2
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.54